Sep 22, 2020
AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center, Rotterdam, Netherlands

Sep 16, 2020
AIM ImmunoTech Highlights Start of Recruitment in Roswell Park Clinical Trial Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19

Sep 10, 2020
AIM ImmunoTech to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14th

Sep 08, 2020
AIM ImmunoTech CEO to Participate in Virtual Panel: 'New Approaches to COVID-19: Hidden Breakthroughs,' on Thursday, September 10th

Aug 27, 2020
AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19

Aug 25, 2020
AIM ImmunoTech to Present at The LD 500 Virtual Conference on September 1st

Aug 17, 2020
AIM ImmunoTech Provides Second Quarter 2020 Business Update and Reports Progress in Both COVID-19 and Cancer Trials

Jul 27, 2020
AIM ImmunoTech to Present at the SNN Network Virtual Investor Conference on Monday, August 3rd

Jul 09, 2020
AIM ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer

Jul 06, 2020
AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19

 1   2   3   4   5     6    7   8   9   10   11